Kolling Institute researcher and Royal North Shore Hospital endocrinologist Professor Rory Clifton-Bligh has been involved in clinical trials for more than 20 years, focusing on conditions such as osteoporosis, thyroid cancer and diabetes. Patients in the endocrinology clinic have sometimes accessed medication 10 years ahead of other Australians. Many of these drugs have gone on to be listed on the.....
Read more

An innovative partnership with industry will see our researchers at the Kolling Institute develop evidence-based strategies to improve osteoarthritis management in Australia and globally. Consumer healthcare company Haleon is sponsoring a five-year fellowship to investigate the role of supplements in managing osteoarthritis and digital health technologies to improve mobility. Osteoarthritis is a le.....
Read more

The Northern Sydney (Arabanoo) Precinct hosted its annual showcase at the Kolling, highlighting the innovative research between the Northern Sydney Local Health District and the University of Sydney. Launched in 2022 by Academic Directors Professors James Elliott, Robyn Gallagher and Margaret Schnitzler, the showcase focused on the joint research tackling complex healthcare challenges. Eight speake.....
Read more

In the heart of the Kolling Institute, a world-renowned research centre, a raft of clinical trials is driving the future of healthcare. “Clinical trials are intrinsic to research,” says Professor James Elliott, Academic Director of the institute. “They help us test something so that we can better inform care for patients with various conditions who come to our hospitals for treatment.” The Kolling .....
Read more

Our researchers at the Kolling Institute are working to improve the use of medications for dementia with a comprehensive analysis highlighting several concerning trends. The latest data indicates more than 420,000 people are living with dementia in Australia, including more women than men. The condition is the second leading cause of death in Australia. Leading researcher and member of the Kolling’.....
Read more

Two of the Kolling Institute’s emerging leaders are gaining attention after receiving the ATA Scientific Encouragement Award. The award, which was launched more than a decade ago, aims to provide young scientists with financial assistance to further their education and attend scientific meetings and conferences. Scientific officer Kevin Winardi from the Kolling’s Lab of Ageing and Pharmacology will.....
Read more

Generous community support is strengthening our research into oesophageal cancer, lifting hopes of improved treatments for the aggressive and deadly cancer. The Fight for a Cure charity has donated $100,000 towards Dr Colby Stevenson’s research, on top of a $100,000 donation from the Howlett family, in memory of their son Scott who died from the cancer. The Howlett family has welcomed the research .....
Read more

Researchers at the Kolling Institute have welcomed the launch of Australia's premier cancer clinical trials centre on the Royal North Shore Hospital campus. NORTH Sydney Trials and Research Van Norton Poche or NORTH STAR VNP has been made possible by a $20 million gift from the late Kay Van Norton Poche and her husband Greg. The centre is a ground-breaking partnership between Northern Sydney Local .....
Read more

Our researchers at the Kolling Institute are at the forefront of Meniere’s disease science developing the first humanised model of the disease ahead of gene therapy. The specialised team is led by world-leading Meniere’s disease researcher and neuroscientist Professor Jose Antonio Lopez-Escamez who relocated from Spain to the institute to pursue his ground-breaking work. His talented team of seven .....
Read more

We may soon have a convenient and painless approach to diagnose chronic kidney disease following research by the team from the Kolling Institute’s Renal Research Laboratory. Chronic kidney disease is an emerging global health issue, currently affecting more than 11 per cent of Australians and 13 per cent of the worldwide population. By 2032, it’s estimated up to 125 million people will have the con.....
Read more